In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Trade Secretary Cristina Roque reported on Saturday that the British-Swedish pharmaceutical AstraZeneca expressed interest in ...

Below is a review of novel drug and biological products approved by the Food and Drug Administration (FDA) in 2024. The list includes several groundbreaking therapies that are expected to change the ...

Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took ...

AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), ...